Filing Flows › Health Care › Tenaya Therapeutics (TNYA)
Tenaya Therapeutics (TNYA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Tenaya Therapeutics (TNYA) Q3 2026 earnings results →
Tenaya Therapeutics made $1.7M in Q3 2026. Operating margin n/m, net loss $18.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.7M in Q3 2026, up 53% from the previous quarter.
Operating costs exceeded revenue by $19.6M, an operating margin of -1153.3%. The quarter ended with a net loss of $18.9M, narrower than the previous quarter's $43.4M loss.
Operating cash flow was −$17.7M. Non-cash charges added back $394K of depreciation and amortization and $1.7M of share-based compensation.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $1.7M | — | n/m | −$18.9M | −$17.7M |
| Q2 2026 | 10-Q | Aug 5, 2026 | $1.1M | — | n/m | −$43.4M | −$3.6M |
| Q1 2026 | 10-Q | May 6, 2026 | $225K | — | n/m | −$19.3M | −$19.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD).
In its own words, from its 8-K, filed Aug 5, 2026.
Tenaya Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TNYA Tenaya Therapeutics | Q3 2026 | $1.7M | — | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Tenaya Therapeutics 10-Q on SEC EDGAR · CIK 1858848 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns TNYA and who is buying
More on TNYA
- How Tenaya Therapeutics makes money: revenue by segment
- Tenaya Therapeutics next earnings date and what analysts expect
- Tenaya Therapeutics stock forecast, price target and fair value
- Who owns Tenaya Therapeutics stock: holders, funds and Congress trades
- Tenaya Therapeutics guidance and outlook
- Tenaya Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results